We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Boston Scientific plans to fully acquire stent developer Veniti—which it already owns 25% of—by buying up the remaining stake in the startup for $108 million upfront......